The Premium On Abbott Laboratories Keeps Growing. So Does The Case For Stryker and Boston Scientific

Abbott Laboratories commands a premium price over faster-growing rivals, forcing investors to decide if its diversified business is worth more than pure-play growth.

For investors in the health care equipment space, Abbott Laboratories (ABT), Stryker (SYK), and Boston Scientific (BSX) represent three distinct ways to own the sector. But the market is pricing them very differently. The central question for an Abbott shareholder is what, exactly, the stock's premium valuation is buying when cheaper, faster-growing alternatives are on the table.

The market currently charges 24.6 times operating income for Abbott. For its peers, the price is significantly lower: 18.8 times for Stryker and just 15.0 for Boston Scientific. Both rivals have posted faster revenue growth over the last twelve months. The valuation gap between Abbott and Stryker has widened over the past year, but not because investors bid up Abbott. Instead, Stryker's multiple compressed, making the choice for investors even sharper.

Abbott's premium buys scale and a confident forecast.

With a market capitalization of about $180.5 billion, Abbott is a diversified giant next to its more focused peers. The company operates across diagnostics, medical devices, nutrition, and established pharmaceuticals, giving it a broad, holistic view of the healthcare system. Management points to its diagnostic testing volumes as a "reliable barometer of overall health care activity," which they say shows "strong and stable demand."

This operational visibility underpins a clear forecast. Management recently reaffirmed its full-year guidance for comparable sales growth of 6.5% to 7.5% and raised its earnings per share guidance to a range of $5.45 to $5.60. This confidence is backed by a pipeline of new products, including the Libre Duo dual glucose-ketone sensor, which secured CE Mark in May, and the Amulet 360 device for atrial fibrillation patients, which Abbott has submitted to the FDA for approval.

The key numbers side by side, today:

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

And the same comparison exactly a year ago, so you can see which way the mismatch has been moving:

OpInc = Operating Income, P/OpInc = Price To Operating Income Ratio

Cheaper peers offer focused growth and higher margins.

Paying for Abbott's stability means forgoing the more concentrated growth stories of its rivals, which also happen to be more profitable. Abbott's own operating income slipped 2.2% over the last twelve months, while both rivals grew theirs by more than 20%. Stryker, for instance, boasts a 21.7% operating margin compared to Abbott's 15.8%. It also recently raised its forward guidance for sales growth. While the stock has faced pressure, its lower multiple presents a clear value proposition for those prioritizing profitability and growth.

Boston Scientific is the cheapest of the three, trading at 15.0 times operating income, and is growing the fastest with 13.5% revenue growth over the last year. A year ago it was the most expensive of the three, at 42.7 times operating income. Its 21.0% operating margin is also well ahead of Abbott's. However, this discount comes with a warning: Boston Scientific recently cut its forward guidance for both revenue and earnings per share. This contrast between strong trailing growth and a weaker outlook is a critical trade-off. For investors interested in this dynamic of a large-cap stock's valuation, a recent analysis of Johnson & Johnson explores why it can command a premium over faster-growing competitors.

The choice turns on Abbott's second-half acceleration.

Ultimately, the decision comes down to an investor's conviction in Abbott's operational plan. The company's premium is the price of its diversified model and management's stated confidence. The alternative is to buy faster growth and higher margins at a lower price, while accepting the risks of a more focused business or a recent guidance cut.

Management has been clear that it expects growth to accelerate in the second half of the year, stating, "We have momentum building across the portfolio." The most direct test of this claim will be whether the company can deliver on its full-year comparable sales growth target of 6.5% to 7.5%. Where the company lands within that range will either validate the premium or suggest the cheaper peers are the better bargain.

Want To Stack Them Up Side By Side Yourself?

You can line Abbott Laboratories and Stryker and Boston Scientific up directly on the Abbott Laboratories peer comparison, weigh them on valuation, growth, margins, and returns, and swap in any other Health Care Equipment names you hold. Or, if you would rather not pick a side at all, a health care ETF like XLV holds Abbott Laboratories, Stryker and Boston Scientific alongside the rest of the group.

Paying The Right Price For Growth Is The Whole Game

This comparison is one instance of the only question that matters in stock picking: how much growth are you getting per dollar you pay? Most portfolios never ask it systematically, which is why most portfolios trail.

The Trefis High Quality (HQ) Portfolio is that question turned into a machine: roughly 30 businesses screened for real growth at defensible prices, held with discipline. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. You just watched the test run on three stocks; own the version that runs on the whole market.